Workflow
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
SanofiSanofi(US:SNY) GlobeNewswire News Room·2025-06-06 16:43

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Sanofi and its officers or directors [1] Group 1: Company Performance - On May 30, 2025, Sanofi released mixed results from a Phase 3 program for itepekimab, an antibody therapy for chronic obstructive pulmonary disease, with the AERIFY-1 trial meeting its primary endpoint while the AERIFY-2 trial did not [3] - Following the announcement, Sanofi's American Depositary Receipt (ADR) price dropped by $2.98, or 5.69%, closing at $49.37 per ADR on the same day [3] Group 2: Legal Investigation - The investigation by Pomerantz LLP is focused on whether Sanofi and certain officers or directors have engaged in securities fraud or other unlawful business practices [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]